What is Qualigen?
Qualigen, Inc. operates at the intersection of diagnostic precision and therapeutic innovation. Leveraging its proprietary nanoparticle coating technology—a foundation established through its FDA-approved FastPack System—the company is actively developing a robust pipeline of novel therapeutics. Key assets include ALAN, a DNA-coated gold nanoparticle candidate designed for high-precision cancer targeting, and RAS-F3, a small-molecule inhibitor aimed at blocking oncogenic mutations. By repurposing its proven diagnostic expertise into the realm of infectious disease and oncology, Qualigen maintains a unique market position that bridges established medical hardware with cutting-edge pharmaceutical research. The company's Carlsbad-based facility serves as the operational hub for these high-stakes development efforts, supported by a global commercial partnership with Sekisui Diagnostics.
How much funding has Qualigen raised?
Qualigen has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Qualigen
PPP
Public-Private Partnership
What's next for Qualigen?
With the recent influx of capital, Qualigen is expected to prioritize the clinical advancement of its core therapeutic candidates. The strategic focus will likely center on navigating the regulatory pathways for its DNA/RNA-based STARS device and accelerating the preclinical and clinical testing of its RAS-F3 inhibitor. As the company moves deeper into late-stage development, the emphasis will shift toward demonstrating the efficacy of its nanoparticle delivery systems in human trials. Investors and industry stakeholders will be monitoring the company's ability to translate its diagnostic-grade manufacturing standards into successful therapeutic outcomes, potentially setting the stage for future licensing agreements or strategic acquisitions within the oncology sector.
See full Qualigen company page
